Cardiovascular Protection with Anti-hyperglycemic Agents.

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus significantly increases cardiovascular (CV) disease risk, accounting for most deaths in diabetic patients.
• Traditional glucose-lowering drugs primarily reduce microvascular complications, with limited impact on macrovascular events like heart attack and stroke.
• Concerns about CV risks associated with some anti-hyperglycemic agents led to regulatory requirements for CV outcome trials.

Purpose of the Study:

• To evaluate the cardiovascular safety and efficacy of newer anti-hyperglycemic agents in patients with diabetes.
• To determine if novel drug classes offer benefits beyond glycemic control for macrovascular outcomes.

Main Methods:

• Analysis of major cardiovascular outcome trials (CVOTs) for new anti-hyperglycemic drug classes, including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors.
• Comparison of CV event rates (major adverse cardiac events, heart failure hospitalizations) between drug treatment groups and placebo.

Main Results:

• GLP-1 analogs (liraglutide, semaglutide) demonstrated significant reductions in major adverse cardiac events (MACE).
• SGLT2 inhibitors consistently showed significant reductions in heart failure hospitalizations, with some also reducing MACE.
• DPP-4 inhibitors showed mixed results, with some trials indicating increased heart failure risk.

Conclusions:

• CVOTs have identified GLP-1 analogs and SGLT2 inhibitors as beneficial for cardiovascular risk reduction in patients with diabetes.
• These drug classes offer advantages beyond glycemic control, impacting major adverse cardiac events and heart failure hospitalizations.
• GLP-1 analogs and SGLT2 inhibitors should be considered alongside lifestyle changes and metformin for managing patients with diabetes and established cardiovascular disease.